← Leaderboards
Andrei V Gudkov
University Of Illinois At Chicago
$19,460,065
Attributed
$20,773,783
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,773,783 · 13
By mechanism
R01$13,465,950 · 8
RC2$5,329,543 · 1
RC1$1,232,695 · 1
R21$720,375 · 2
R03$25,220 · 1
Top collaborators
- Marina Antoch5 shared
- Michelle Haber3 shared
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsMediatingP53 Gene /ProteinCellsBaseGene ExpressionMolecularTumorProteinsGenesOncogenesTumor Suppressor GenesPharmaceutical PreparationsDrug ResistanceNeoplasm /Cancer GeneticsGene Expression ProfilingNeoplastic CellMalignant NeoplasmsFlagellinPathway InteractionsInsightMonitorTissuesNormal Cell
Grant awards (53)
Targeting retrotransposons for improved treatment of refractory childhood cancer$360,013
R01 · FY2025 · CA · contact PI
Targeting retrotransposons for improved treatment of refractory childhood cancer$224,100
R01 · FY2025 · CA · contact PI
Targeting retrotransposons for improved treatment of refractory childhood cancer$602,486
R01 · FY2024 · CA · contact PI
"Combining radiation with TLR5 agonist based immunotherapy against liver metastases"$189,986
R21 · FY2020 · CA · contact PI
"Combining radiation with TLR5 agonist based immunotherapy against liver metastases"$227,984
R21 · FY2019 · CA · contact PI
An intercross between the circadian and NFkB pathways$361,486
R01 · FY2014 · GM
An intercross between the circadian and NFkB pathways$328,401
R01 · FY2013 · GM
An intercross between the circadian and NFkB pathways$83,333
R01 · FY2013 · GM
Controlling Radiation Injury by TLR5 Agonists$348,710
R01 · FY2012 · AI · contact PI
An intercross between the circadian and NFkB pathways$335,934
R01 · FY2012 · GM
Controlling Radiation Injury by TLR5 Agonists$344,263
R01 · FY2011 · AI · contact PI
An intercross between the circadian and NFkB pathways$331,683
R01 · FY2011 · GM
Mechanisms of mitigation of radiation damage of GI tract by Protectan CBLB502$2,485,184
RC2 · FY2010 · AI · contact PI
Controlling Radiation Injury by TLR5 Agonists$343,378
R01 · FY2010 · AI · contact PI
Mechanisms of mitigation of radiation damage of GI tract by Protectan CBLB502$2,844,359
RC2 · FY2009 · AI · contact PI
Protectan CBLB502$458,512
RC1 · FY2009 · AI · contact PI
Controlling Radiation Injury by TLR5 Agonists$342,570
R01 · FY2009 · AI · contact PI
GENETIC ELEMENTS TRANSFORMING MOUSE FIBROBLASTS$265,865
R01 · FY2009 · CA · contact PI
Protectan CBLB502$774,183
RC1 · FY2008 · AI · contact PI
Controlling Radiation Injury by TLR5 Agonists$338,417
R01 · FY2008 · AI · contact PI
GENETIC ELEMENTS TRANSFORMING MOUSE FIBROBLASTS$263,714
R01 · FY2008 · CA · contact PI
Diagnostic Therapeutic Targets in Prostate Cancer$369,102
R01 · FY2007 · CA · contact PI
Modulators of p53 Expression and Function$343,545
R01 · FY2007 · CA · contact PI
GENETIC ELEMENTS TRANSFORMING MOUSE FIBROBLASTS$183,900
R01 · FY2007 · CA · contact PI
GENETIC ELEMENTS TRANSFORMING MOUSE FIBROBLASTS$106,838
R01 · FY2007 · CA · contact PI
Diagnostic Therapeutic Targets in Prostate Cancer$27,693
R01 · FY2007 · CA · contact PI
Diagnostic Therapeutic Targets in Prostate Cancer$332,425
R01 · FY2006 · CA · contact PI
GENETIC ELEMENTS TRANSFORMING MOUSE FIBROBLASTS$302,544
R01 · FY2006 · CA · contact PI
Modulators of p53 Expression and Function$280,880
R01 · FY2006 · CA · contact PI
ISSA: novel functional approach to cancer-related genes$149,405
R21 · FY2006 · CA · contact PI
Protecting immune system by modulators of p53 and NF-kB$1,500,000
R01 · FY2005 · AI
Diagnostic Therapeutic Targets in Prostate Cancer$340,425
R01 · FY2005 · CA
GENETIC ELEMENTS TRANSFORMING MOUSE FIBROBLASTS$309,825
R01 · FY2005 · CA
Modulators of p53 Expression and Function$287,640
R01 · FY2005 · CA
ISSA: novel functional approach to cancer-related genes$153,000
R21 · FY2005 · CA
Diagnostic Therapeutic Targets in Prostate Cancer$340,425
R01 · FY2004 · CA
Modulators of p53 Expression and Function$287,640
R01 · FY2004 · CA
STRESS INDUCED BYSTANDER EFFECT IN CANCER TREATMENT$275,400
R01 · FY2004 · CA
Diagnostic Therapeutic Targets in Prostate Cancer$331,525
R01 · FY2003 · CA
Modulators of p53 Expression and Function$287,640
R01 · FY2003 · CA
STRESS INDUCED BYSTANDER EFFECT IN CANCER TREATMENT$266,400
R01 · FY2003 · CA
GENETIC ELEMENTS TRANSFORMING MOUSE FIBROBLASTS$266,400
R01 · FY2003 · CA
GENETIC ELEMENTS TRANSFORMING MOUSE FIBROBLASTS$266,400
R01 · FY2002 · CA
STRESS INDUCED BYSTANDER EFFECT IN CANCER TREATMENT$266,400
R01 · FY2002 · CA
STRESS INDUCED BYSTANDER EFFECT IN CANCER TREATMENT$294,368
R01 · FY2001 · CA
GENETIC ELEMENTS TRANSFORMING MOUSE FIBROBLASTS$266,400
R01 · FY2001 · CA
MODULATORS OF P53 EXPRESSION AND FUNCTION$217,021
R01 · FY2001 · CA
GENETIC ELEMENTS TRANSFORMING MOUSE FIBROBLASTS$27,968
R01 · FY2001 · CA
MODULATORS OF P53 EXPRESSION AND FUNCTION$6,777
R01 · FY2001 · CA
GENETIC ELEMENTS TRANSFORMING MOUSE FIBROBLASTS$294,368
R01 · FY2000 · CA
STRESS INDUCED BYSTANDER EFFECT IN CANCER TREATMENT$294,368
R01 · FY2000 · CA
MODULATORS OF P53 EXPRESSION AND FUNCTION$217,280
R01 · FY2000 · CA
GENETIC ELEMENTS SUPPRESSING P53$25,220
R03 · FY2000 · TW